# Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)

> **NCT04432324** · PHASE2 · COMPLETED · sponsor: **Instituto Grifols, S.A.** · enrollment: 100 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Intravenous Immune Globulin
- **DRUG:** Standard Medical Treatment

## Key facts

- **NCT ID:** NCT04432324
- **Lead sponsor:** Instituto Grifols, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-02
- **Primary completion:** 2021-03-03
- **Final completion:** 2021-03-03
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04432324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04432324, "Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04432324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*